Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.6950
-0.0285 (-3.94%)
At close: Oct 2, 2026, 4:00 PM EDT
0.7001
+0.0051 (0.73%)
After-hours: Oct 2, 2026, 7:30 PM EDT
← View all transcripts

AGM 2026

Jun 16, 2026

Summary

The meeting covered director elections, auditor ratification, a reverse stock split, and executive compensation, with all proposals approved by stockholders. No questions were raised, and final voting results will be filed in a Form 8-K.

Operator

Hello and welcome to the annual meeting of stockholders of Aprea Therapeutics. Please note that today's meeting is being recorded. It is now my pleasure to turn today's meeting over to Dr. Oren Gilad, President and Chief Executive Officer of the company. Please go ahead, sir.

Oren Gilad
President and CEO, Aprea Therapeutics

Thank you, operator, and good morning. This meeting is officially called to order. I'm Oren Gilad, President and CEO of the company, and I will be presiding as Chairman of this meeting. I want to welcome you to the 2026 annual meeting of the stockholders of Aprea Therapeutics, Inc. John Hamill, Senior Vice President and Chief Financial Officer of the company, will act as Secretary of the meeting. We have chosen to conduct this annual meeting in a virtual format, and we're pleased to be able to hold a meeting that a stockholder can attend virtually from anywhere, enabling everyone to engage with the company. With that, I will turn the meeting over to the secretary for some brief introductory comments.

John Hamill
SVP and CFO, Aprea Therapeutics

Thank you, Oren. The rules of conduct and procedures for this meeting are posted on the virtual meeting website. As stated in those rules for the stockholders attending via the web portal, questions regarding matters to be voted on at the meeting can now be submitted through the web portal. Also, as an important reminder, if you voted your shares prior to the start of the annual meeting, whether by proxy card, internet or phone, your vote has been received by the company's Inspector of Elections and there is no need to vote those shares again during the annual meeting unless you wish to revoke or change your vote. Back to you, Mr. Chairman.

Oren Gilad
President and CEO, Aprea Therapeutics

Thank you. As an administrative matter, I would like to introduce you to the company's Directors, all of whom are in virtual attendance for today's meeting. In addition to me, the company's Directors are as follows: Jack Henneman, Marc Duey, Richard Peters, who's also the Chairman of the Board, Mike Grissinger, Gabriela Gruia, Refik Pamukcu, Bernd Seizinger, and Jean-Pier re Bizzari. In addi ti on, the company's independent registered public accounting firm, EisnerAmper LLP, is present and is represented by Marc Pallo, who is available to answer any questions from stockholders that are directed to the auditors. With that, we will begin the formal business of the meeting. The meeting has been called pursuant to due notice. Proxies were solicited on behalf of the Board of Directors of the company for this meeting. The company has appointed Jenna Bentley of Borden Consulting Group, LLC to act as Inspector of the Elections.

Jenna Bentley is with us today and will act as the Inspector of Elections for the meeting. The Inspector of Elections has already delivered the oath of office to the Secretary. At the close of business on April 21st, 2026, the record for this meeting, the company had 12,382,077 outstan ding shares of common stock, which constitute the only outstanding securities of the company entitled to vote at this meeting. Each share of common stock entitled the holder of record thereof to on e vote. Under applicable law and the bylaws of the company, for there to be quorum for consideration of any matter at this meeting, there must be present in person or by proxy, the holder of the majority of shares of common stocks.

We're informed by the Inspector of Elections that there are indeed represented in person or by proxy shares of common stock representing at least a majority of the shares of the common stock of the company. I declare that quorum is present for the matters contemplated to be consid ered at this annual meeting of stockholders, and the meeting is ready to proceed with business set forth on the ag en da. The polls are now open at 9:00 A.M. Eastern, June 16, 2026. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further actions. Any stockholder who has not yet voted or wish to change their vote may do so by clicking on the voting button at the web portal and following the instructions there.

Voting at this meeting would revoke any previously submitted proxy. We will pause briefly to allow any final votes to be cast. The board of directors recommend that you vote for or in favor of each item. I now open the meeting for questions regarding matters to be voted on at the meeting, which we will address now. Any question regarding matters of general company concerns, which we address following th e conclusion of formal business at the meeting. Please refer to the rules and conduct procedures for this meeting for further information regarding our procedures for answering questions from stockholders. Mr. Secretary, are there any questions?

John Hamill
SVP and CFO, Aprea Therapeutics

Mr. Chairman, there are no questions about items to be voted on at the meeting.

Oren Gilad
President and CEO, Aprea Therapeutics

Thank you. The first order of business is the election of three Class directors to hold office for three-year terms expiring at the 2029 annual meeting of stockhold ers until their respective successors will have been duly elected and qualified.

The board of directors has nominated Marc Duey, Richard Peters, and Bernd Seizinger, each of whom is currently a director of the company and named as a n ominee in the company's proxy statement to serve as directors of the company to hold office for a three-year term expiring at the 2029 annual meeting of stockholders, until their respective successors shall have been duly elected and qualifie d.

The second order of business on our agenda is the proposal to ratify the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the 2026 fiscal year.

The third order of business on our agenda is the proposal to approve an amendment to the company's amended and restated certificate of incorporation and to authorize the board of directors to effect a reverse stock split of the common stock at a ratio not less than one for three and not more than one for eight of the common stock, with all fractional shares rounded up to the nearest whole share, with the exact ratio to be set within this range by the board in its sole discretion, without reducing the authorized number of shares of the common stock, and with a reverse stock split to be effected such time and date, if at all, as determined by the board in its sole discretion. The fourth order of business on our agenda is the proposal to approve, on an advisory basis, the compensation of our named executive officers.

The fifth order of business on our agenda is the proposal to approve, on an advisory basis, the frequency of future advisory say on pay votes. The final order of business on our ag enda is the proposal to approve the adjournment of the annual meeting if necessary to solicit additional proxies if there are no sufficient votes in favor of proposal three. At this time, I ask any stockholder who desire to vote to p lease conclude their voting through the virtual meeting website. The polls are now closed at 9:10 A.M. Eastern, June 16, 2026. We will now return to the results of the balloting on the item on our agenda. Will the Corporate Secretary please submit the report of the Inspector of Elections on the results of the balloting.

John Hamill
SVP and CFO, Aprea Therapeutics

We have been informed by the Inspector of Elections that the preliminary vote report shows that each of the nominees for director has been elected. In addition, the ratification of the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the 2026 fiscal year has been approved by our stockholders. The amendment to the company's amended and rest ated certificate of incorporation has been approved by the stockholders, and the board is authorized to affect a reverse stock split of the common stock at a ratio of not less than one for three and not more than one for eight of the common stock, with all fractional shares rounded up to the nearest whole share. With the exact ratio to be set within this range by the board in its sole discretion, without reducing the authorized number of shares of the common stock.

With the reverse stock split to be affected at such time and date, if at all, as determined by the board in its sole discretion. The compensation of our named executive officers has been approved by non-binding ad visory vote by our sto ckholders. The frequency of future advis ory votes on the compensation of our annual named executive officers will be on an annual basis. The adjournment of the annual meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of proposal three, has been approved by our stockholders. We will be reporting the final voting results in a Form 8-K to be filed within four business days.

Oren Gilad
President and CEO, Aprea Therapeutics

Thank you. The Inspector of Elections will execute a certificate as to the result of the balloting, and the certificate will be filed in the minute book of the company, along with the minute of this meeting. We will now proc eed into the Q&A session to address some of the previously submitted questions from the stockholders in accordance with our webcast meeting rules. Seeing that there are no questions, we will proceed to conclude the meeting. Our Q&A session will now conclude. The meeting is adjourned. Thank you very much for your attendance.

Operator

This concludes today's meeting. You may now disconnect.